Pravastatin potentiates the anticoagulant effects of low molecular weight heparin

Zimmer, Jennifer; Spillert, C. R.; Puppala, Sirisha; Zamecki, Katherine; Bhatt, B.A.; Arora, Rohit

doi:10.1016/j.thromres.2004.02.020

Cited by 5 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A Dutch study that assessed the immediate and long-term effects of new statin use on the dosage of vitamin K antagonist (VKA) showed that statin users needed lower doses of VKA to achieve the target INR, with the most substantial effect seen with simvastatin and rosuvastatin [ 28 ]. Pravastatin was also noted to potentiate the anticoagulant effects of dalteparin [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study

et al. 2021

View full text Add to dashboard Cite

Background Statins are a potential treatment for venous thromboembolism (VTE) prophylaxis complementary to conventional anticoagulants without associated bleeding complications. This study aimed to compare pro-thrombotic activities of different classes of lipid-lowering drugs in an active comparator design and determine whether there is a relation between statin versus fibrate/niacin use and pro-coagulant factor outcomes. Methods This is a cross-sectional analysis of participants from the Netherlands Epidemiology of Obesity study using any class of lipid-lowering drugs, including any types of statins, niacin, and fibrates. We performed linear regression analyses to determine fibrinogen, factor (F) VIII, FIX, and FXI activity in statins versus fibrate/niacin users and adjusted for age, sex, tobacco smoking, body mass index (BMI), hypertension, diabetes, and prevalent cardiovascular disease. Results Among 1043 participants, the mean age was 58.4 ± 5.2 years, 61% were men, and the mean BMI was 31.3 ± 4.5 kg/m2. Clinical characteristics were balanced between statin and fibrate/niacin users. Statin users had lower mean FXI (18.3 IU/dL, 95% confidence interval (CI) 9.4 to 27.3) levels compared to fibrate/niacin users. The level of FVIII (15.8 IU/dL, 95% CI − 0.003 to 31.6), and FIX (11.3 IU/dL, 95% CI − 0.4 to 23.2) were lower in statin users than fibrate/niacin users with marginal statistical significance. Conclusion Current statin use was associated with lower plasma levels of FXI than fibrate/niacin use. The effects on coagulation factors may, in part, explain the benefit of statin therapy rendered in primary and secondary prevention of VTE.

show abstract

Section: Discussionmentioning

confidence: 99%

Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A Dutch study that assessed the immediate and long-term effects of new statin use on the dosage of vitamin K antagonist (VKA) showed that statin users needed lower doses of VKA to achieve the target INR, with the most substantial effect seen with simvastatin and rosuvastatin [27]. Pravastatin was also noted to potentiate the anticoagulant effects of dalteparin [28].…”

Section: Discussionmentioning

confidence: 99%

Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study

Bordbar

Mutsert

Cevval

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Statins are a potential treatment for venous thromboembolism (VTE) prophylaxis complementary to conventional anticoagulants without associated bleeding complications. The aim of this study was to compare prothrombotic activities of different classes of lipid-lowering drugs in an active comparator design, and determine whether there is a relation between statin versus fibrate/niacin use and procoagulant factor outcomes.Methods: This is a cross-sectional analysis of participants from the Netherlands Epidemiology of Obesity study who were using any class of lipid-lowering drugs, including any types of statins, niacin, and fibrates. We performed linear regression analyses to determine the activity of fibrinogen, factor (F)VIII, FIX, and FXI in statins versus fibrate/niacin users and adjusted for age, sex, tobacco smoking, body mass index (BMI), hypertension, diabetes, and prevalent cardiovascular disease.Results: Among 1043 participants, the mean age was 58.39± 5.19 years, 61% were men, and mean BMI was 31.3± 4.5 kg/m2. Clinical characteristics were balanced between statin and fibrate/niacin users. Statin users had lower mean FVIII (15.8 IU/dL, 95% confidence interval (CI) -0.003 to 31.6), FIX (11.3 IU/dL, 95% CI -0.4 to 23.2) and FXI (18.3 IU/dL, 95% CI 9.4 to 27.3) levels, and higher mean fibrinogen levels (19.1 mg/dL, 95% CI -10.0 to 48.2) compared to fibrate/niacin users.Conclusion: Current statin use was associated with lower plasma levels of FVIII, FIX, FXI, and higher fibrinogen levels compared to fibrate/niacin use. These effects on coagulation factors may, in part, explain the benefit of statin therapy rendered in primary and secondary prevention of VTE.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2004

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Pravastatin potentiates the anticoagulant effects of low molecular weight heparin

Cited by 5 publications

References 15 publications

Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study

Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study

Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About